Cargando…

Burden of Clostridium difficile on the Healthcare System

There are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority of studies focus on the costs of CDI in acute-care facilities. Analysis of the best available data, from 2008, indicates that CDI may have resulted in $4.8 billion in excess costs in US acute-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubberke, Erik R., Olsen, Margaret A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388018/ https://www.ncbi.nlm.nih.gov/pubmed/22752870 http://dx.doi.org/10.1093/cid/cis335

Ejemplares similares

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings
por: Durham, David P., et al.
Publicado: (2016)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population
por: Olsen, Margaret A, et al.
Publicado: (2018)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Current State of Clostridium difficile Treatment Options
por: Venugopal, Anilrudh A., et al.
Publicado: (2012)

Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach
por: Desai, Kamal, et al.
Publicado: (2016)

Current Status of Clostridium difficile Infection Epidemiology
por: Lessa, Fernanda C., et al.
Publicado: (2012)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Attributable Outcomes of Endemic Clostridium difficile–associated Disease in Nonsurgical Patients
por: Dubberke, Erik R., et al.
Publicado: (2008)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis
por: Dubberke, Erik R., et al.
Publicado: (2016)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management
por: Eyre, David W., et al.
Publicado: (2012)

ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease
por: Dubberke, Erik R., et al.
Publicado: (2006)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis
por: Bauer, Martijn P., et al.
Publicado: (2012)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
por: Sears, Pamela, et al.
Publicado: (2012)

Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence
por: Lewis, Brittany B., et al.
Publicado: (2017)

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

The Burden of Clostridium difficile after Cervical Spine Surgery
por: Guzman, Javier Z., et al.
Publicado: (2015)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

Outpatient Healthcare Settings and Transmission of Clostridium difficile
por: Jury, Lucy A., et al.
Publicado: (2013)

The Epidemiology and Economic Burden of Clostridium difficile Infection in Korea
por: Choi, Hyung-Yun, et al.
Publicado: (2015)

525 Epidemiology and burden of recurrent Clostridium difficile infections
por: Sheitoyan-Pesant, Caroline, et al.
Publicado: (2014)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

2322: The effects of fecal microbiota transplantation on the gut microbiota in subjects with Clostridium difficile infection
por: Elizabeth Langdon, Amy, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Prevalence of Clostridium difficile colonization among healthcare workers
por: Friedman, N Deborah, et al.
Publicado: (2013)

Navigating changes in Clostridioides difficile prevention and treatment
por: Durham, Spencer H, et al.
Publicado: (2020)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Burden of Clostridium difficile Infections in Québec by Levy et al
por: Longtin, Yves, et al.
Publicado: (2016)

CRISPR Diversity and Microevolution in Clostridium difficile
por: Andersen, Joakim M., et al.
Publicado: (2016)

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2016)

Emergence and global spread of epidemic healthcare-associated Clostridium difficile
por: He, Miao, et al.
Publicado: (2012)

Characteristics of Clostridium difficile isolates and the burden of hospital-acquired Clostridium difficile infection in a tertiary teaching hospital in Chongqing, Southwest China
por: Dai, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7lp75d5gb10idqbmec19pqa8ds